Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588523 · ClinicalTrials.gov registry record · Phase 2
Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
A Phase 2 study of CNS Cancer and CNS Brain, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT00588523 is a Phase 2 study of CNS Cancer and CNS Brain that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT00588523, a Phase 2 study of CNS Cancer and CNS Brain, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to see how effective treatment of high doses of chemotherapy is for your tumor. We will also be looking at the side effects and risks of this treatment. You will receive very high doses of chemotherapy. High doses of chemotherapy can destroy tumor cells, but it can also destroy normal bone marrow cells. These cells produce white blood cells (which fight infection), red blood cells (which carry oxygen) and platelets (which allow your blood to clot). With too few of these cells there is a serious risk of infection and bleeding. Therefore, before treatment begins, we will collect some of your own blood cells, called peripheral blood progenitor cells (PBPCs). These cells help create new blood cells. The PBPCs are frozen and saved while you are being treated. Then at the end of treatment, your PBPCs are thawed and given back to you. These healthy PBPCs will replace the blood cells that the high dose chemotherapy destroys and allow your bone marrow to recover and produce blood cells. In a prior study we treated 69 patients in a similar way. More than half were able to avoid or delay brain radiation. This new study will use a different high dose chemotherapy regimen.
Conditions Studied
Interventions
- DRUG temozolomide followed by high dose busulfan and thiotepa
Study Locations (3)
New York
- Memorial Sloan Kettering Cancer Center - Commack
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-09 |
| Est. Completion | 2023-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588523
The ClinicalTrials.gov registry entry for NCT00588523 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with CNS Cancer appearing as the primary indexed condition, and to 1 intervention - of which temozolomide followed by high dose busulfan and thiotepa is the first listed.
NCT00588523 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00588523 about?
NCT00588523 is a clinical study titled "Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma". The purpose of this study is to see how effective treatment of high doses of chemotherapy is for your tumor. We will also be looking at the side effects and risks of this treatment. You will receive very high doses of chemotherapy. High doses of chemotherapy can destroy tumor cells, but it can also...
What is the current status of trial NCT00588523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2002-09. Estimated completion is 2023-02-02.
What conditions does trial NCT00588523 study?
This clinical trial studies the following conditions: CNS Cancer, CNS Brain.
What interventions are being tested in trial NCT00588523?
The interventions under investigation include: temozolomide followed by high dose busulfan and thiotepa (DRUG).
Who is sponsoring clinical trial NCT00588523?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00588523 being conducted?
This trial has 3 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CNS Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.